NMTC Form 4: CEO Sells 2,458 Shares at $0.8886 — Holds 1.16M

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) director and CEO David A. Rosa reported a small sale of 2,458 shares of common stock at $0.8886 per share on 09/30/2025, leaving beneficial ownership of 1,156,373 shares.

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) director and CEO David A. Rosa reported a small sale of 2,458 shares of common stock at $0.8886 per share on 09/30/2025, leaving beneficial ownership of 1,156,373 shares. The filing documents a routine insider disposition while the reporting person retains a substantial equity stake, and the transaction was disclosed under Section 16 rules.

Insights

Financial Analyst

TL;DR: Small insider sale; ownership remains substantial, so market impact is likely minimal.

The reported sale of 2,458 shares for $0.8886 each represents a very small reduction relative to the remaining 1,156,373 shares beneficially owned. From a financial perspective, the transaction is immaterial to company capitalization and does not indicate a significant change in the insider's economic exposure. The disclosure meets Section 16 transparency requirements and allows investors to track insider activity.

Corporate Governance Expert

TL;DR: Filing demonstrates compliance; the CEO remains a major shareholder after the sale.

As both director and CEO, the reporting person's continued large shareholding is relevant to governance and alignment with shareholders. The small sale could reflect personal liquidity needs or routine transactions rather than a shift in corporate control or governance stance. Full compliance with Form 4 filing formalities is evident from the provided disclosure.

Insider Trade Summary

Exercise Price or Tax Liability: 2,458 shares

Exercise Price or Tax Liability 1 txn

Insider Rosa David A

Role CEO and President

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,458	$0.8886	$2K

Holdings After Transaction: Common Stock — 1,156,373 shares (Direct)

FAQ

What insider transaction did NMTC CEO David A. Rosa report?

The filing reports a sale of 2,458 common shares at $0.8886 per share on 09/30/2025.

How many NMTC shares does David A. Rosa own after the reported sale?

After the transaction, the reporting person beneficially owns 1,156,373 shares.

Does the Form 4 filing for NMTC indicate a change in control?

No. The sale is small relative to the remaining holdings and does not indicate a change in control based on the disclosed figures.

Who signed the Form 4 for the NMTC transaction?

The filing shows the Form 4 was signed by an agent using power of attorney, consistent with standard disclosure practice.

Was the insider transaction by NMTC material to company valuation?

Based on disclosed amounts, the sale of 2,458 shares is immaterial relative to the reported 1,156,373 shares held and is unlikely to materially affect valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/01/2025 - 02:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Rosa David A

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		F		2,458	D	$0.8886	1,156,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Emily Johns, by Power of Attorney	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.